Liang Zhang

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by RealPage, Inc. of 5,847,457 shares of its common stock (which included…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by The Travelers Companies, Inc. of $500 million aggregate principal amount…

Davis Polk advised the representatives of the several underwriters in connection with the registered offering by DXC Technology Company of $500 million aggregate principal amount of 4.000%…

Davis Polk advised the underwriters in connection with an SEC-registered offering of $750 million aggregate principal amount of 2.950% notes due 2029 and $1.25 billion aggregate principal…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $380 million acquisition of HemaCare Corporation. The proposed purchase price equates to $25.40…

Davis Polk advised the initial purchasers in connection with a Rule 144A/Regulation S offering by AES Gener S.A. of an aggregate principal amount of $450 million of 6.350% junior…

Davis Polk advised the underwriters in connection with an SEC-registered offering by AbbVie Inc. of €1.4 billion aggregate principal amount of senior notes in two series, consisting of €750…

Davis Polk advised the joint book-running managers in connection with an offering by Beazer Homes USA, Inc. of $350 million aggregate principal amount of its 7.250% notes due 2029. Davis…

Davis Polk advised the joint book-running managers in connection with the SEC-registered offering by Deciphera Pharmaceuticals, Inc. of 10,810,810 shares of common stock for gross proceeds…

Davis Polk advised the underwriters in connection with an SEC-registered offering of $1 billion aggregate principal amount of 2.950% notes due 2029 and $400 million aggregate principal…